Johnson & Johnson said on Tuesday its drug Prezista was as effective in a late-stage trial as Abbott Laboratories Inc's Kaletra in cutting HIV to undetectable levels among patients not previously treated with HIV drugs.
Prezista, a once-daily protease inhibitor recently introduced by J&J, was given to patients along with Abbott's older protease inhibitor Norvir (ritonavir) and Gilead Science Inc's widely used Truvada. Truvada itself contains two drugs belonging to a separate class of HIV treatments called nucleoside reverse transcriptase inhibitors.
read more
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment